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Introduction
Crude animal venom contains a diverse mixture of bioactive 
compounds that target a variety of receptors to support survival 
of venomous animals.1 However, venoms and their metabolites 
are now being recognised as potential exploitable tools in medi-
cine.2,3 As such, the term ‘venomics’ was first used by Juárez et al4 
to describe characterisation of the complete protein profile of 
snake venom. Following on from this, more recent advances in 
analytical techniques including incorporation of genomics, mass 
spectrometry and proteomics have assisted scientists to more 
easily explore venom profiles.5 Together with modern-day ability 
to rapidly screen venom compounds using high-throughput 
assays, this represents a step-change in realising the full thera-
peutic potential of animal venoms.5 This review summarises cur-
rent clinically approved venom-based drugs, and briefly considers 
venom-derived drugs in clinical trials as well as use of venom 
products as cosmeceuticals before finally highlighting the thera-
peutic promise of such compounds for obesity-diabetes.
Clinically Approved Venom-Derived Drugs
Captopril and enalapril
Ferreira et al6 purified and characterised bradykinin-potentiat-
ing factors (BPFs) from the Brazilian viper snake venom, 
which the Squibb Institute of Medical Research was then able 
to utilise teprotide, which acted as an ACE inhibitor.7 After 
studying structure/function aspects of teprotide, the orally 
active compound named SQ 14 225 (D-2-methyl-3-
mercaptopropanoly-L-proline), now better known as captopril 
was generated (Table 1), and was the first ACE inhibitor that 
effectively lowers blood-pressure in humans.7-9 Following cap-
topril, enalapril was synthesised by the substitution of the mer-
capto group present on the captopril structure, to an alkyl 
group.10 Despite limited oral bioavailability, the prodrug dis-
plays good potency and was clinically approved in 1985 as 
Vasotec, for the treatment of hypertension and congestive heart 
failure.11-13
Ziconotide
Ziconotide is an intrathecal analgesic drug that was clinically 
approved in 2004 for the treatment of chronic pain14 (Table 1). 
Marketed as Prialt, this 25 amino acid peptide is a synthetic 
version of ω-conotoxin MVIIA (ω-MVIIA), extracted from 
the venomous cone snail Conus magus.14-16 It has been demon-
strated that ω-conotoxin blocks N-type voltage gated calcium 
channels and prevents the release of pro-nociceptive neuro-
chemicals including glutamate, calcitonin gene-related peptide 
and substance P.17-19 Prialt is also used to treat chronic pain in 
those with intolerances to morphine or other systemic 
analgesics.20
Eptifibatide and tirofiban
Tirofiban was the first approved venom-derived antiplatelet 
drug based on the structure of echistatin, a peptide extracted 
from venom of the saw-scaled viper, Echis carinatus21 (Table 1). 
Echistatin, isolated in 1988, is a glycoprotein (GP) IIb/IIIa 
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receptor antagonist leading to effective inhibition of fibrinogen-
induced platelet aggregation.21-25 Furthermore, Scarborough 
et  al26 screened 62 snake venoms, leading to the discovery of 
barbourin from the pygmy rattle snake, Sistrurus miliarius, that 
specifically inhibited GP IIb/IIIa receptors. These findings 
ultimately led to the synthesis of eptifibatide (Table 1), a highly 
effective antiplatelet drug.27,28
Lepirudin and bivalirudin
Lepirudin and bivalirudin (Table 1) are specific thrombin 
inhibitors, with structures based on hirudin, a peptide with 
strong anticoagulant properties found in blood-sucking leeches, 
Hirudo medicinalis.29,30 Lepirudin was clinically approved in 
1998, and bivalirudin followed in 2000.31 In 2012, lepirudin 
was discontinued, although this was not due to inefficacy or 
adverse effects, but rather manufacturing issues.32 Bivalirudin, 
on the other hand is still routinely prescribed to treat unstable 
angina and percutaneous coronary intervention.33-35
Batroxobin
Batroxobin (Table 1), isolated from the venom of the Bothrops 
moojeni venomous snake is a thrombin-like serine protease 
which is a defibrinogenating agent with anti-inflammatory 
effects.36,37 Batroxobin is a 231 amino acid protein that helps to 
form non-cross-linked fibrin clots and subsequently release 
fibrinopeptides A.38,39 Purified from B. Moojeni venom, it is 
marketed as Defibrase and currently available for use in China 
for the treatment of stroke and ischemic attack.40,41
Apitox
Bee venom extracted from Apis mellifera and marketed as 
Apitox has been clinically approved in South Korea for the 
treatment of osteoarthritis42,43 (Table 1). This approval came 
after a phase III clinical trial with 363 patients with knee oste-
oarthritis.44 Furthermore, Apimeds are sponsoring a clinical 
trial for use of apitox in the treatment of Multiple Sclerosis 
(MS), as the drug is believed to be effective in reducing pain 
and swelling associated with the disease but there are no clini-
cal data currently available in this regard.45
Cobratid
A short-chain α-neurotoxin isolated from cobra venom Naja 
naja atra, is known to act as an antagonist of nicotinic acetyl-
choline receptors (nAChRs) and bring about analgesic effects.46 
As such, in a rodent model of pain, cobratid exerted dose-
dependent analgesic effects that were independent of mus-
carinic ACh and opioid receptor modulation.47 Furthermore, 
cobratid, now promoted as a tablet named Keluoqo that also 
contains tramadol hydrochloride and ibuprofen, has undergone 
clinical trials for the treatment of moderate to severe pain asso-
ciated with cancer.48 Whilst results of this study were promis-
ing, issues around development of tolerance still need to be 
addressed. However, it should be noted that studies are ongo-
ing in a bid to help minimise adverse effects associated with use 
of this drug.49-51
Exenatide
Oral glucose administration results in a greater insulinotropic 
response compared to similar intravenous glucose delivery in 
humans.52 This phenomenon, known as the ‘incretin effect’, is 
related to the secretion of the gut-derived hormones glucagon-
like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP).53 Both hormones act on specific pancreatic 
beta cell G-protein-coupled receptors (GPCRs), that stimulate 
adenylyl-cyclase activity, cAMP accumulation and ultimately 
Table 1. Origin, treatment indication and current methods for production of currently clinically approved venom-derived drugs.
DRUG SPECIES TREATMENT INDICATION PRODUCTION
Captopril and Enalapril 
(Capoten, Vasotec)
Brazilian viper, Bothrops jararaca Hypertension and related 
cardiovascular disorders
Synthetic
Ziconotide (Prialt) Cone snail, Conus magus Chronic pain Synthetic
Eptifibatide and Tirofiban 
(Integrilin, Aggrastat)
Saw-scaled viper, Echis carinatus Thrombotic cerebrovascular or 
cardiovascular disease
Synthetic
Pygmy rattle snake, Sistrurus miliarius
Lepirudin and Bivalirudin 
(Refludan, Angiomax)
Blood-sucking leech, Hirudo medicinalis Stroke, deep vein thrombosis and 
pulmonary embolism
Synthetic
Batroxobin (Defibrase) Brazilian lancehead snake, Bothrops 
moojeni
Stroke and ischemic attack and 
sudden deafness
Purified from venom
Bee venom therapy (Apitox) Bee, Apis mellifera Osteoarthritis Whole venom
Exenatide (Byetta, Bydureon) Gila Monster lizard, Heloderma suspectum Type 2 diabetes Synthetic
Cobratoxin (Cobratid) Chinese cobra, Naja naja atra Pain Purified from venom
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insulin secretion.54 In type 2 diabetes, secretion of GLP-1 from 
the GI tract is blunted following nutrient intake highlighting 
an ideal drug target for the disease.55 However, native GLP-1 
has a short biological half-life due to degradation by the ubiqui-
tous enzyme dipeptidyl peptidase-4 (DPP-4) upon secretion 
into the bloodstream, limiting therapeutic application of this 
peptide. DPP-4 has a wide substrate specificity and acts on vari-
ous regulatory peptides, chiefly cleaving small peptides with 
proline or alanine as the penultimate N-terminal residue.56 As 
such, although DPP-4 inhibitor drugs are now clinically 
approved for the treatment of type 2 diabetes with an excellent 
adverse effect profile, lack of substrate specificity was an initial 
concern.56 In this respect, the first clinically approved GLP-1 
peptide mimetic with inherent stability against DPP-4 was 
derived from the saliva of the venomous Gila monster lizard, 
Heloderma suspectum.57,58 The peptide, first isolated by Eng 
et al57 was named exendin-4 and shown to have 53% homology 
to human GLP-1. Importantly, exendin-4 possesses an amino 
acid substitution at the penultimate N-terminal residue that 
masks the DPP-4 binding site and dramatically extends the 
duration of biological action of the peptide58 (Figure 1; Table 1). 
Exendin-4 was initially marketed as Byetta (Figure 2), and then 
later as an extended release preparation known as Bydureon, 
which were approved for clinical use in 2005 and 2017, respec-
tively, for the treatment of type 2 diabetes.
Venom and Cosmeceuticals
Cosmeceuticals represent an attractive avenue for commercial 
use of venom-derived products. This is typified by the global 
success of Botulinum toxin (Botox) based therapies for medical 
and particularly cosmetic purposes, where Botox represents a 
type A toxin isolated from Clostridium botulinum bacteria.59 
The toxin acts on neuromuscular junctions to prevent acetyl-
choline (ACh) release from presynaptic neurons, subsequently 
causing mild muscle paralysis.60 Indeed, since first use of Botox 
for a cosmeceutical procedure to decrease the appearance of 
wrinkles in 1989, the drug now generates around $3 billion per 
annum.61,62 In a separate venture, snake venom has also entered 
the cosmeceutical industry for use in facial serums to reduce 
wrinkles. An example of this being the use of synthetic tripep-
tide (Tripeptide [SYN®-AKE]) from Tropidolaemus wagleri 








Figure 1. The amino acid sequence of exenatide in comparison to native GLP-1. The key amino acid substitution at position 2 that confers full resistance 
to DPP-4 in exenatide is highlighted.
Figure 2. A schematic showing proposed insulin secretory pathways for the venom-derived peptides hanatoxin grammotoxin, guangtoxin, exendin-4, 
conkunitzin-S1, iberiotoxin and melittin within pancreatic beta cells. A simplified pathway for the secretion of insulin via the primary beta cell stimulus, 
namely glucose, is depicted for reference via conversion to glucose-6-phospahate, with subsequent generation of ATP and closure of KATP channels. 
Colour coded numbers correspond to proposed beta-cell membrane target of each venom-derived peptide, with the specific K+ channel that melittin binds 
to still not known. Indeed, the mechanisms of all peptides, barring exendin-4, still needs to be fully characterised. Abbreviations: ADP, adenosine 
diphosphate; ATP, adenosine triphosphate; BK, calcium-activated (big) potassium channel; cAMP; cyclic adenosine monophosphate; GLUT, glucose 
transporter 2; GPCR, G-protein coupled receptor; Kv, voltage-gated potassium channel.
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waglerin 1, which also blocks the action of ACh to subse-
quently inhibit muscle contraction.63 Additionally, venom 
purified from the Apis mellifera L. honeybee is also currently 
being exploited in facial serums as it is believed to reduce total 
wrinkle size in individuals with UV damage.64 Most recently, 
argiotoxine-636 (ArgTX-636) isolated from the Argiope lobata 
spider venom has been patented for its use in skin and teeth 
whitening.65 Although the mechanism of action of ArgTX-
636 remains to be fully elucidated, inhibitory effects on mel-
anogenesis is believed to be key in these cosmeceutical 
applications.66 In terms of approval processes, it is important to 
note the differences in regulatory authorisation for a drug and 
a cosmeceutical. As such, a cosmeceutical is considered to exert 
a pharmaceutical therapeutic benefit but not necessarily linked 
to an established biological benefit.67 Therefore, unlike drugs, 
the FDA does not necessarily review or approve cosmeceuticals 
prior to sale, representing a much simpler approval process 
than with drugs. However, there is still some controversy 
around the exact boundaries of what constitutes a cosmeceuti-
cal and a drug,68 that requires further detailed clarification.
Venom-Derived Drugs in Clinical Trials
Early clinical trials
There has been much effort made to utilise natriuretic pep-
tides, namely atrial natriuretic peptide (ANP), ventricular 
natriuretic peptide (BNP) and C-type natriuretic peptide 
(CNP) for the treatment of heart failure.69-71 The first charac-
terised reptilian natriuretic peptide, dendroaspis natriuretic 
peptide (DNP), was extracted from the Eastern green mamba 
snake Dendroaspis angusticeps.72 DNP, a 38 amino acid peptide 
that has structural similarities to human natriuretic peptides, is 
a potent activator of cardiomyocyte guanylate cyclase A, which 
aids in cardiac unloading and therefore may have benefits in 
heart failure.73,74 Cenderitide, a derivative of DNP, was synthe-
sised and developed by the Mayo Clinic through fusion of the 
22 amino acid peptide CNP with the 15 amino acid C-terminal 
of DNP.74 A clinical trial was conducted in 2015 by Capricor, 
to assess efficacy and safety of subcutaneous infusion of cend-
eritide in subjects with stable, chronic heart failure.75 Although 
the drug was well tolerated, further clinical assessment of cen-
deritide by Capricor has not been carried out. However, a phase 
I clinical trial by Mayo Clinic with cenderitide in 30 partici-
pants with myocardial infarction was completed in 2019.76
Another approach for utilising snake venom involved the 
extraction of the enzyme metalloproteinase fibrolase from the 
southern copperhead snake Agkistrodon contortrix contor-
trix.77,78 The protein consisting of 203 amino acids, underwent 
DNA recombination to create alfimeprase, a compound which 
directly degrades fibrin to result in thrombolysis.79-81 
Alfimeprase successfully underwent a phase I clinical trial in 
patients with acute peripheral arterial occlusion (PAO) and 
was well tolerated with no reports of bleeding or systemic 
thrombolysis.82 Although alfimeprase progressed to phase II 
and III trials, these were terminated as there was ultimately no 
significant improvement when compared to placebo.82,83
The discovery and success of ziconotide from Conus magus 
has brought much attention to the potential of marine venom-
derived compounds. Therefore, it is not surprising there has 
been the extraction and characterisation of such peptides, pro-
gressing into clinical trials. Firstly, Vc1.1 a 16 residue α-
conotoxin (ACV1) from Conus victoriae is a potent antagonist 
of nAChRs, where modulation of nAChR’s is associated with 
clear analgesic actions.84,85 Metabolic Pharmaceuticals con-
ducted a phase I human clinical trial with ACV1 in healthy 
males, where it was well tolerated, and no adverse effects 
reported.86 However, lack of efficacy in phase IIa trials for dia-
betic peripheral neuropathic pain led to further clinical research 
with ACV1 being discontinued, but α-conotoxins are still 
being explored as future drugs for the treatment of neuropathic 
pain.87-89
In another attempt to exploit a conotoxin with analgesic 
properties, the χ-conotoxin χ-MrIA, was extracted from the 
Conus marmoreus.90 The 13-residue peptide was found to non-
competitively inhibit the norepinephrine transporter (NET) in 
humans,91 whereby inhibiting the reuptake of norepinephrine 
has demonstrated analgesic properties.91 Thus, Xen2174, a 
synthetic version of χ-MrIA with the addition of a pyrogluta-
myl residue to the N terminus, demonstrated analgesic effects 
in a rat model of neuropathic pain.92 Whilst Xen2174 dis-
played promising results in a phase II clinical trial for cancer 
patients with chronic pain, it ultimately failed to pass into 
phase IIb due to dose-limiting toxicity.2 Lastly, contulakin-G 
is a 16 amino acid peptide extracted from the Conus geographus 
and was shown to inhibit neurotensin receptors (NTRs).93,94 
Neurotensin is a peptide found in the CNS with an influence on the 
internal analgesic system. 95In this regard, contulakin-G, later 
named CGX-1160, received orphan drug status in 2005, after 
the success of a phase Ib clinical trial for the treatment of neu-
ropathic pain associated with spinal cord injury, but has since 
been discontinued.96
Another venomous animal with perceived therapeutic value 
is the vampire bat Desmodus rotundus, specifically through iso-
lation of a 441 amino acid fibrin-dependent plasminogen acti-
vator from its venom.97,98 Later named desmoteplase, this 
thrombolytic agent effectively breaks down blood clots by con-
verting plasminogen to plasmin.97 Desmoteplase was investi-
gated as a potential therapeutic agent for ischemic stroke,99 
however, despite promising initial observations, desmoteplase 
was subsequently terminated following lack of prominent effi-
cacy in a phase III clinical trial.100-102
Current clinical trials
Cancer. Chlorotoxin is a 36 amino acid peptide extracted from 
the venom of the Deathstalker scorpion, Leiurus quinquestra-
tius,103 which has shown specificity towards various cancerous 
cell lines including glioma, melanoma and carcinoma.104 It is 
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theorised that chlorotoxin can specifically target chloride ion 
channels on glioma tumour cells to prevent malignancy and 
decrease tissue invasion potency.105,106 As of January 2020, the 
City of Hope Medical Centre in California began recruiting 
participants for phase I testing of the safety and efficacy of 
chlorotoxin for recurrent glioblastoma cancer.107 The trial will 
involve the delivery of chimeric antigen receptor (CAR-T lym-
phocytes), with chlorotoxin as the tumour targeting domain. 
CAR-T lymphocytes are synthetic T cell receptors that can 
recognise tumours and activate an immune response specific to 
the cancerous cells.108 An additional use of chlorotoxin is with 
tozuleristide (Table 2), a tumour targeting agent that comprises 
chlorotoxin and the fluorescent dye, indocyanine green that 
provides intraoperative visualisation of tumours.109,110 Tozuler-
istide successfully underwent a phase I clinical trial in 17 
patients diagnosed with glioma, treatable by surgical excision. 
The trial revealed no adverse effects and good tolerability of 
tozuleristide, as well as being highly effective in glioma imag-
ing.111 More recently, Blaze Bioscience Inc. is recruiting paedi-
atric patients with CNS tumours undergoing surgery for use of 
tozuleristide in phase II and III trials.112
In an alternative approach, cancer cell growth has been 
linked to increased ambient calcium levels, with the Transient 
Receptor Potential Vanilloid channels (TRPV6) known to play 
a key role in regulating normal calcium homeostasis.113 
Overexpression of TRPV6 within some cancerous cell lines 
such as breast, pancreatic and ovarian has been detected.113,114 
Interestingly, a peptide named SOR-C13 (Table 2), modelled 
on a 253 amino acid protein extracted from the venom of the 
northern short-tailed shrew, Blarina brevicauda, has been 
shown to prevent calcium uptake via TRPV6.115 As such, a 
clinical trial enrolling patient with solid tumours such as pan-
creatic and ovarian,116 ultimately lead to SOR-C13 being 
awarded orphan drug status for both ovarian and pancreatic 
cancer.116 More recently, the Anderson Cancer Centre in Texas 
is currently recruiting patients with advanced refractory solid 
tumours for treatment with SOR-C13. This is a phase Ib trial 
that will determine the most effective dose of SOR-C13 in 
these patients.117
Autoimmune disease. As well as cancer, there are also ongoing 
clinical trials with venom-derived compounds in auto-immune 
disease. In this regard, in 1996 a 35 amino acid peptide called 
Stichodactyla toxin (ShK) was extracted from a Caribbean Sea 
anemone Bunodosoma granulifera and shown to block Kv1.3 
potassium channels118 (Table 2). ShK-186, a 37 amino acid 
analogue of ShK, now known as dalazatide, successfully under-
went a Phase I trial consisting of 32 healthy volunteers, dis-
playing only mild adverse effects and good tolerability.119 In 
addition, in a Phase Ib trial for psoriasis in 2014, dalazatide was 
extremely well tolerated.120 This is particularly encouraging 
given the current lack of effective treatment options for those 
with autoimmune disease, and the increasing prevalence of the 
disease worldwide. Furthermore, TEKv Therapeutics (Colum-
bus, OH) are currently preparing Phase II clinical trials for the 
treatment of autoimmune diseases such as lupus and erythema-
tous with dalazatide.
Additionally, cobratoxin and cobrotoxin from Naja atra 
cobra snake venom has entered clinical trials for the treatment 
of a range of diseases. Cobratoxin and cobrotoxin have been 
detoxified to produce chemically modified versions, namely 
RPI-78M (Receptin) and RPI-MN (Pepteron), respectively 
(Table 2). The peptides displayed analgesic effects by specifi-
cally targeting nAChRs.121-123 Additionally, RPI-78M proved 
safe and effective in a phase I clinical trial for the treatment of 
MS.2 RPI-MN has also proved effective in a preclinical study 
against the human immunodeficiency virus, as it has shown an 
ability to inhibit viral replication.124
Emerging Venom-Derived Drugs for Type 2 Diabetes
Overview of type 2 diabetes
Type 2 diabetes is a complex metabolic disorder characterised 
by insulin resistance, as well as a decrease in pancreatic beta cell 
mass and insulin secretion, that ultimately leads to overt 
Table 2. Details of venom-derive drugs undergoing clinical trials including name, origin, treatment indication and clinical trial phase progression.
DRUG SPECIES TREATMENT INDICATION CLINICAL TRIAL PHASE
Chlorotoxin (CTx) Deathstalker scorpion, Leiurus 
quinquestratius
Recurrent glioblastoma cancer Phase 1 [NCT04214392]
Chlorotoxin with 
tozuleristide (BLZ-100)
Deathstalker scorpion, Leiurus 
quinquestratius
Central nervous system tumours Phase I and phase II 
[NCT03579602]
SOR-C13 (Sorcidin) Northern short-tailed shrew, 
Blarina brevicauda
Advanced refractory solid tumours Phase Ib [NCT03784677]
ShK-186 (Dalazatide) Caribbean sea anemone, 
Bunodosoma granulifera
Lupus and erythematous Phase II
RPI-78M (Receptin) Chinese cobra, Naja naja Multiple sclerosis and adrenomyeloneuropathy Phase II and phase III
RPI-MN (Pepteron) Chinses cobra, Naja naja Amyotrophic lateral sclerosis, herpes simplex 
keratitis and human immunodeficiency virus
Phase I and phase II
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hyperglycaemia.125,126 If the disease is poorly managed several 
complications can arise, including cardiovascular and kidney 
disorders, blindness and neurogenerative disorders.127,128 
Diabetes is described as one of largest epidemics of the 21st 
century with the prediction that 642 million people will suffer 
from diabetes by 2040.129 The treatment for obesity-related 
diabetes is initially education and lifestyle intervention, but 
such strategies are often ineffective, and patients inevitably 
progress to pharmacological treatment.130 There is an array of 
drugs available to treat 2 diabetes that can improve insulin 
secretion (sulfonylurea and meglitinide) or sensitivity (thiazo-
lidines and metformin), enhance the incretin effect (GLP-1 
mimetics and DPP-4 inhibitors), increase glucose excretion 
(sodium glucose transporter 2 inhibitors) or ultimately insulin 
replacement therapy as the last line of treatment.131,132 
Although these drugs are effective, they are often associated 
with adverse effects such as weight gain and hypoglycaemia.131 
Additionally, drug failure over time is commonplace with type 
2 diabetes therapeutics, leading to polypharmacy and ineffec-
tive blood glucose control.132,133 Therefore, it is essential that 
new pharmacological agents are developed to provide more 
effective treatment for diabetes, with less adverse effects that 
should improve compliance and overall clinical outcomes.
The discovery of exendin-4 from the venom of the Gila 
monster, as noted above, has brought much attention and 
acceptability to the use of venom-derived drugs in the field of 
diabetes therapies. Unlike other antidiabetic agents, exendin-4 
has much fewer side effects such as hypoglycaemia and 
encourages weight loss.134 Additionally, it has been demon-
strated that exendin-4 increases beta cell proliferation and 
protects against cardiovascular disorders.135,136 To date, prod-
ucts derived from the venoms of bees, cone snails, sea anemo-
nes, scorpions, snakes and spiders are being actively 
investigated as new and effective therapeutic approaches for 
diabetes,137 with exendin-4 recognised as clear proof-of-con-
cept for this exciting drug discovery route.
Cone snail insulin
Human insulin is composed of 2 peptide chains linked by 2 
disulphide bonds, chain A contains 21 amino acids and chain B 
which contains 30 amino acids.138 Con-Ins G is an insulin mol-
ecule derived from the Conus geographus cone snail that lacks 
the C-terminus of the B chain but can activate human insulin 
receptors.139,140 Additionally, unlike human insulin, Cons-Ins 
G1 has a lower affinity for the primary binding site on the 
human insulin receptor (hIR), with a preferential affinity for the 
secondary binding site, suggesting an alternative mechanistic 
approach to hIR activation.141 Furthermore, this insulin peptide 
contains post-translational modifications in the A and B chain, 
namely a γ-carboxylated glutamate residue and a hydroxylated 
proline residue, respectively, which have been hypothesised to 
increase biological activity.141 In this regard, the crystal structure 
of Con-Ins G1 in comparison to human insulin has been 
described.141 The discovery of Cons-Ins G1 has led to the syn-
thesis of a new recombinant insulin analogue, with an extremely 
fast onset of action due to its smaller size.141 Moreover, the 
small size of the peptide means chemical synthesis is less com-
plicated, making it a prime candidate for the development of a 
new insulin therapeutic regimen for humans141 (Table 3). Thus, 
Cons-Ins G1 could represent another important option within 
the array of clinically approved insulin analogues or could have 
use in premixed insulin combinations.137
In a separate approach to utilise cone snail venom, there was 
the isolation of Conkunitzin-S1 (Conk-S1) form the cone 
snail Conus striatus.142 This peptide was shown to specifically 
inhibit Kv1.7 beta cell channels (Figure 2), which resulted in an 
increase in glucose-stimulated insulin secretion from rat islets. 
However, unlike current insulinotropic therapeutics such as 
sulfonylureas and meglitinides, conk-S1 is not associated with 
hypoglycaemia as glucose-dependent stimulation of insulin 
secretion has been observed.143 The NMR-derived solution 
structure of recombinant Conk-S1 has been revealed, exhibit-
ing 2 disulphide bonds.142 As such, conk-S1 represents a tool to 
help characterise Kv1.7 channel mechanisms involved in insu-
lin secretion and could also prove to be a valuable novel thera-
peutic option for type 2 diabetes.143
Caribbean sea anemone
As well as their role in the immune system, Kv1.3 channels have 
been implicated in the development of insulin resistance and sub-
sequently type 2 diabetes.144 This is evident from Kv1.3 gene 
deletion studies in mice, resulting in enhanced peripheral insulin 
sensitivity and anti-satiety effects.145 Thus, Shk-186 was admin-
istered to diet-induced obese mice, resulting in normalisation of 
blood glucose and insulin, as well body weight reduction.146 The 
anti-obesity mechanism of action has not been fully established. 
However, it has been suggested that Shk-186 contributes to 
improved peripheral insulin sensitivity through activation of 
brown adipose tissue, or via reduction of obesity-induced inflam-
mation of abdominal white adipose tissue.146 These results were 
similar to that observed with Kv1.3 gene deletion, supporting the 
role of Kv1.3 in insulin resistance.145 However, it should also be 
noted that Kv1.3 channel blockade did not reduce body weight 
gain in diet-induced obese rats,147 and whilst this might be related 
to subtle differences in dosing regimens and animal models 
employed, it does necessitate further study on the anti-obesity 
potential of Kv1.3 inhibition. Although, it has already been dem-
onstrated in clinical trials that ShK-186 has a good safety profile, 
further promoting potential therapeutic promise for obesity and 
insulin resistance.
Snake venom
Poor glycaemic control in diabetes can lead to an increased risk 
of damage to blood vessels in the eyes known as diabetic retin-
opathy.148 Indeed, type 2 diabetes is now the leading cause of 
























































































































































































































































































































































































































































































































































































































































































blindness in the UK.149 Blindness usually arises due to an angio-
genesis cascade leading to neovascularisation from the retinal 
vessel in a process called choroidal angiogenesis.150 In this regard, 
integrins are receptors that have been implicated in angiogene-
sis.150 Lebecetin is a C-type lectin extracted from the blunt-nose 
viper snake, Macrovipera lebetina, which has been shown to 
interact with α5β1- and αv-containing integrins.150 C-type lec-
tins represent a class of snake proteins which have been impli-
cated in anticoagulant- and platelet-modulating activities. In 
one study, lebecetin is demonstrated to reduce angiogenesis in a 
chorioallantoic membrane assay and effectively decrease the 
extent of choroidal neovascularisation.150 Importantly, lebecetin 
was specific towards the proliferating vascular cells rather than 
the mature blood vessels suggesting it would be a safe and effec-
tive treatment for choroidal angiogenesis.150
Sulfonylureas and meglitinides are approved classes of type 2 
diabetes drugs that target the ATP-sensitive potassium (KATP) 
channel on pancreatic beta cells to promote insulin secretion.151 
However, a major disadvantage of these insulin secretagogues is 
non-glucose dependent insulin release and subsequent hypogly-
caemia.152 Thus, constituents of snake venom could yield prod-
ucts that help give a better understanding of these beta cell 
signalling pathways, leading to drug modifications and a reduc-
tion in side effect profiles. As such, the venom from the mono-
cle cobra snake, Naja kaouthia, was analysed and fractioned, 
leading to the isolation of Cardiotoxin-1.153 Cardiotoxins have 
previously demonstrated cytotoxicity and cell damage however, 
this peptide was demonstrated to be non-toxic to the rodent 
beta cell-line INS-1.153 Cardiotoxin-1 stimulates insulin release 
in a dose-dependent manner, but this effect is independent of 
glucose concentrations. Whilst the mechanism of action has yet 
to be fully established, an increase in beta-cell intracellular cal-
cium is observed with cardiotoxin-1 and action at Kv channels 
has been hypothesised.153 Thus, it could be utilised to gain a 
better understanding of the important Kv channel-dependent 
insulin secretory pathway in pancreatic beta cells.154 In addition, 
Moore et al isolated insulin releasing compounds from Crotalus 
adamanteus, Crotalus vegrandis and Bitis nasicornis snakes by gel 
filtration chromatography. The insulinotropic action appeared 
to be linked to serine proteinases, phospholipases A2 (PLA2) 
and disintegrins within the venom.155 PLA2 belong to a group 
of snake toxins with insulinotropic abilities, as exposure results 
in hydrolysis of membrane phospholipids, the production of 
arachidonic acid and subsequently insulin secretion.156,157 
Additionally, disintegrins represent a class of snake peptides 
that have been implicated in anti-platelet activity but may also 
possess effects on beta cell insulin secretion.158
Finally, a crotamine-like protein was extracted from the 
venom of the south American rattlesnake Crotalus durissus cas-
cavella that displayed glucose-dependent insulin secretory 
actions.159 Crotamine is one of the main toxins of the American 
rattlesnake and has previously be shown to be non-toxic to 
human endothelial, fibroblasts and muscle cells.160,161 Although 
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the insulinotropic effects have not been fully elucidated, it may 
be linked to modulation of Na+ channels. The putative mecha-
nism of action comes from it inducing membrane depolarisa-
tion-dependent muscle contractions by increasing the Na+ 
permeability of skeletal muscle membrane.162 The glucose-
dependent nature of the peptide could represent a major thera-
peutic advantage over other classes of antidiabetic drugs, as 
already noted with exendin-4.
Wasp and bee venom
The most abundant class of peptides found within wasp venom 
are known as mastoparans.163 It has previously been shown that 
mastoparans stimulate the release of insulin in the presence or 
absence of glucose, however phospholipase A2 was required for 
this biological action.164 This suggests an interaction between 
beta cell GPCRs and mastoparan, leading to activation of 
phospholipase A2 and subsequent insulin release.164 
Furthermore, agelaia MP-1 is a 14 amino acid mastoparan 
peptide isolated from the venom of the social wasp Agelaia pal-
lipes pallipes (Table 3; Figure 3), with 3D structure predicted by 
computer software packages.165 Agelaia MP-1 was shown to 
induce mast cell degranulation as well as stimulate insulin 
secretion.165 Importantly, insulinotropic actions were not 
related to beta cell lysis, and interestingly persisted despite 
inhibition of the Ca2+ and KATP channels, suggesting GPCR 
interaction and activation of subsequent second messenger cell 
signalling pathways.165 However, there has been some concern 
about bee venom and its non-specific mode of action and pos-
sible adverse side effects.166 Nonetheless, melittin is recognised 
as a potential anti-diabetic agent and studies are underway to 
reduce or neutralise related toxicity, without detrimentally 
affecting therapeutic promise. This includes polymer nanopar-
ticle delivery systems appear to significantly reduce, or even 
annul, toxicity.167,168 Further to this, melittin derived from bee 
venom belongs to a class of gating modifier toxins (GMTS) 
that modulate voltage-gated ion channels and possibly stimu-
late insulin secretion through interaction with beta cell K+ 
channels169 (Figure 2). A GMTS nanocomplex was formulated 
to extend duration of action and prevent possible toxicity, with 
strong electrostatic interactions between negatively charged 
polyanions, dextran sulphate (DS) and the positively charged 
melittin.169 The formation of this (DS)/melittin nanocomplex 
successfully increased the half-life of melittin and reduced its 
acute toxicity in concert with controlling blood-glucose levels 
for 48 hours in diabetic mouse models.169
Moreover, bee venom may not only improve glycaemic con-
trol, but can also help wound healing, a classic complication of 
diabetes.170 Bee venom is known for its antimicrobial and anti-
inflammatory qualities, suggesting potential for the improve-
ment of this complication.171 Therefore, it is not surprising that 
diabetic rodents treated with bee venom display improved 
wound healing, in studies that not only improve our under-
standing of diabetic wound healing processes, but also suggests 
bee venom as a potential therapeutic option.171 The mecha-
nism of anti-inflammatory effects of bee venom are still not 
fully understood. However, gene expression studies demon-
strate ability of bee venom to inhibit lipid accumulation and 
downregulate adipogenic transcription factors, such as PARγ 
and C/EBPα.172 Furthermore, bee venom was recently shown 
to improve GLUT-4 expression and insulin sensitivity sug-
gesting bee venom as a potential treatment for chronic inflam-
mation in obesity as well as diabetes.172 Indeed, venom from 
the Egyptian honeybee Apis mellifera lamarckii, improved dia-
betic status in alloxan treated rats.173 Beneficial effects were 
believed to be related to the melittin and phospholipase A2 
components of the venom.173 Finally, diabetes and prolonged 
periods of hyperglycaemia can lead to protein glycation and 
impairment of biological activity.174 In this respect, honeybee 
Apis mellifera venom reduced the extent of glycation of haemo-
globin in an in vitro assay over a 5-week incubation period,175 
with a mechanism linked to preventing the binding of glucose 
Figure 3. 2D structural information for hanatoxin, grammotoxin and agelaia MP-1 based on known amino acid sequences.
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to haemoglobin, and therefore preventing glycation induced 
changes in the haemoglobins secondary structure.175
Scorpion venom
As noted above, The Kv channel mode of action on pancreatic 
beta cells includes repolarisation of the membrane and limiting 
Ca2+ entry into the beta cell.176,177 In this regard, there has 
been identification of beta cell calcium-activated potassium 
BK (big potassium) channels.178 This channel is activated upon 
Ca2+ influx into the beta cell and subsequent membrane depo-
larisation. In this regard, a peptide extracted from the Eastern 
Indian red scorpion Buthus tamulus, named iberiotoxin is an 
antagonist of this channel,137,179 with its 3D structure available 
from the uniport number provided (Table 3). Iberiotoxin has 
been shown to increase the duration of the beta cell action 
potential by delaying rectifier currents, and subsequently 
increase insulin secretion in human pancreatic beta cells.137,179 
However, whilst iberiotoxin has helped with understanding of 
beta cell secretory dynamics, therapeutic promise could be 
compromised by lack of specificity, as BK channels also play an 
important role in the CNS.180 Thus, further study into the 
therapeutic potential and safety profile of iberiotoxin in diabe-
tes is still required.
Spider venom
Two K+ ion channel modifier peptides, named hanatoxin and 
grammotoxin (Table 3; Figure 3), were successfully extracted 
from the venom of the Chilean rose tarantula Grammostola 
rosea.137,181 Hanatoxin is a 35 amino acid peptide with 6 
cysteine residues181 and is described as a potent inhibitor of the 
Kv2.1 component of the K+ repolarisation beta cell chan-
nel181,182 (Figures 2 and 3). Interestingly, the peptide is known 
to insert itself into the phospholipid membrane hydrocarbon 
core, without the requirement of pore formation, before it then 
encounters and inhibits the Kv channel inside the membrane 
phospholipid.183,184 It has been demonstrated that the peptide 
can also inhibit the Kv2.2 channels, but with a lower infinity.137 
In keeping with this, hanatoxin increases glucose-stimulated 
insulin secretion and calcium oscillators in both mouse and 
human islets.2 Grammotoxin exhibits 43% amino acid sequence 
homology to hanatoxin and is believed to have a similar mech-
anism (Figure 3), but it binds to the same Kv channels with 
lower affinity185,186 (Figure 2). However, whilst comparison of 
the 3D structures of hanatoxin and grammotoxin does reveal 
some clear conservation of structures between both peptides, 
slight differences in the surface shape and distribution of the 
charged residues may help explain the lower binding affinity of 
grammotoxin.186 Following on from this, guangtoxin (GxTX) 
has been extracted from the Plesiophrictus guangxiensis taran-
tula187,188 (Table 3). GxTX has been shown to broaden the 
length of the glucose-induced beta cell action potential and 
increase related Ca2+ oscillations through interaction with the 
Kv channel, whilst being ineffective at low glucose levels, thus 
limiting potential to cause hypoglycaemia.187,188
Although exciting in terms of potential therapeutic value, 
a disadvantage is the widespread expression of Kv channels, 
and it may prove challenging to specifically target beta cell Kv 
channels.137 However, inhibition of the Kv2.1 channel has 
been demonstrated to promote beta cell survival in streptozo-
tocin-diabetic mice, demonstrating clear potential as a type 2 
diabetes therapeutic.189 Furthermore, in comparison to snake 
venoms, the study and application of spider venom peptides 
as potential diabetes therapeutics is somewhat limited. This is 
most likely a direct reflection of the amount of venom that 
can be milked, and subsequently analysed and tested, from a 
snake as opposed to a spider. However, it should be acknowl-
edged that the majority of current peptide discovery efforts 
focus more on genomics and transcriptomics to identify 
potentially interesting sequences, which are then synthesised 
or expressed, rather than relying on extraction from the ani-
mal. Nonetheless, spider venoms are conservatively predicted 
to contain more than 10 million bioactive peptides, many of 
which have never been investigated, making them a valuable 
resource for peptide-based drug discovery.190 Additionally, 
although venom-derived peptides are generally extremely 
enzymatically stable in the circulation, their administration 
will likely still require parenteral delivery to avoid proteases 
activity within the stomach. However, major strides have been 
taken in terms of oral formulation of peptides, including clin-
ical trials with insulin, GLP-1, calcitonin, parathyroid hor-
mone and vasopressin.191 Given the wealth of peptides present 
in spider venom and this prospect of oral delivery, they pro-
vide an ideal subject matter for exploration in relation to 
insulin secretion from pancreatic beta cells, and merit much 
further study in this regard.
Conclusion
Advances in biological methodologies has allowed for the dis-
covery and characterisation of more animal venom-derived 
compounds with potential therapeutic or cosmeceutical appli-
cation. The success of clinically approved drugs in this field, as 
well as others undergoing clinical trials and some well-estab-
lished cosmeceuticals such as Botox, only serves to strengthen 
this viewpoint. In particular, approval of exendin-4 as a first in 
class therapeutic for diabetes, highlights the possibility of 
future antidiabetic agents being derived directly from venom 
constituents. Although this is an extremely exciting area of 
drug discovery, further studies are needed to dissect the under-
lying mechanisms, safety profile and possible requirement for 
tissue-targeting of currently characterised compounds in this 
field. Indeed, off-target effects may see many of these toxin 
products utilised only as research tools to better understand 
pancreatic beta-cell function, rather than clinically approved 
therapeutics or useful cosmeceuticals. However, in particular, 
more investigation into the unquestionable untapped thera-
peutic potential of spider venom peptides is still required.
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